We create innovative solutions for the treatment of nervous system damage due to trauma or disease.
NervGen is a publicly traded (TSX-V: NGEN, OTCQX: NGENF) clinical stage biotech company dedicated to developing novel drugs for the treatment of spinal cord injury, multiple sclerosis and Alzheimer’s disease.
Sign up to our newsletter
In this inspiring and heartfelt video, Dr. Jerry Silver, Professor of Neurosciences, Case Western Reserve University, shares his journey and how the research carried out in his lab led to the formation of NervGen.
The video highlights how NervGen is developing Dr. Silver’s foundational discoveries into a disruptive technology that is aimed at changing the paradigm of how nervous system damage will be treated.
Media
By Codi Darnell November 15, 2022 It may feel like fall just arrived, but we are one month away from winter. Yes, winter is coming
News Release
Chronic spinal cord injury cohort results expected in mid-2024 Subacute spinal cord injury cohort results expected in late 2024/early 2025 Vancouver, Canada, September 25,
Article
NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. The company’s lead target indication is spinal cord injury.
Contact
2955 Virtual Way
Suite 480
Vancouver, BC V5M 4X6
Phone: (778) 731-1711
Email: info@nervgen.com